Mavrilimumab, a human monoclonal antibody targeting GM-CSF receptor-α, in subjects with rheumatoid arthritis: a randomised, double-blind, placebo-controlled, phase I, first-in-human study

OBJECTIVE: To evaluate the safety, tolerability, pharmacokinetic and pharmacodynamic profiles of mavrilimumab, a human monoclonal antibody targeting the granulocyte-macrophage colony-stimulating factor receptor-α, in subjects with rheumatoid arthritis (RA). METHODS: A randomised, double-blind, place...

Descripción completa

Detalles Bibliográficos
Autores principales: Burmester, Gerd R, Feist, Eugen, Sleeman, Matthew A, Wang, Bing, White, Barbara, Magrini, Fabio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Group 2011
Materias:
Clinical and Epidemiological Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3147227/
https://www.ncbi.nlm.nih.gov/pubmed/21613310
http://dx.doi.org/10.1136/ard.2010.146225

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3147227/
https://www.ncbi.nlm.nih.gov/pubmed/21613310
http://dx.doi.org/10.1136/ard.2010.146225

Ejemplares similares